Primary care might be the first setting where AI-driven tools allow for broader access to effective melanoma screening, amid continuing challenges in developing consumer apps for this purpose.
A federal advisory panel offered a bevy of suggestions about how the FDA might proceed with potential future clearances for the broad use of tools intended to analyze skin lesions for cancer risk.
STOCKHOLM, March 23, 2022 /PRNewswire/ SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today its inclusion